| http://www.w3.org/ns/prov#value | - Novartis is a leading pharmaceutical manufacturer with a strong commitment to the care of the oncology patient, and we look forward to working with CMS to improve access and quality of care for Medicare beneficiaries requiring cancer treatment.Novartis would like to commend CMS for its thoughtful review of the off-label uses of oxaliplatin, irinotecan, cetuximb, and bevacizumab in the treatment of
|
